Novel Mechanisms of Resistance to Investigational Molecularly Targeted Drugs
نویسندگان
چکیده
منابع مشابه
Mechanisms of resistance to EGFR-targeted drugs: lung cancer
Despite the improvement in clinical outcomes derived by the introduction of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) in the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumours harbour EGFR-activating mutations, prognosis remains unfavourable because of the occurrence of either intrinsic or acquired resistance. We reviewed th...
متن کاملMolecularly targeted drugs for metastatic colorectal cancer
The survival rate of patients with metastatic colorectal cancer (mCRC) has significantly improved with applications of molecularly targeted drugs, such as bevacizumab, and led to a substantial improvement in the overall survival rate. These drugs are capable of specifically targeting the inherent abnormal pathways in cancer cells, which are potentially less toxic than traditional nonselective c...
متن کاملResistance to HER2-targeted therapy
Production and approval of trastuzumab (Herceptin®) for the treatment of metastatic breast cancer (MBC) was a millstone in antibody-based targeted therapy in the cancer treatment. However, despite the early success in the clinical trials, trastuzumab failed to appreciate the initial attraction due to development of resistance to the drug. The majority of patients who benefit from the drug...
متن کاملThe current state of molecularly targeted drugs targeting HGF/Met.
Met is a tyrosine kinase that has hepatocyte growth factor as its ligand. Met plays a major role in cell growth, migration and morphological changes. Overexpression of hepatocyte growth factor and Met and mutations and amplification of MET have been noted in many forms of cancer and are reportedly correlated with cancer progression and a poor prognosis. Over the past few years, these molecules ...
متن کاملThe regulation of investigational drugs.
THE search for effective drugs to combat the acquired immunodeficiency syndrome (AIDS) has focused renewed attention on the process by which the U.S. Food and Drug Administration(FDA) regulates the development and availability of new therapeutic agents. The federal government’s ability to strike the difficult balance between ensuring the safety of patients and accelerating the availability of n...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: YAKUGAKU ZASSHI
سال: 2017
ISSN: 0031-6903,1347-5231
DOI: 10.1248/yakushi.16-00229-6